327 related articles for article (PubMed ID: 17657689)
1. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
[TBL] [Abstract][Full Text] [Related]
2. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Nelson M
Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
[No Abstract] [Full Text] [Related]
3. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Shah GK; Sang DN; Hughes MS
Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
[TBL] [Abstract][Full Text] [Related]
4. Evolving European guidance on the medical management of neovascular age related macular degeneration.
Chakravarthy U; Soubrane G; Bandello F; Chong V; Creuzot-Garcher C; Dimitrakos SA; Korobelnik JF; Larsen M; Monés J; Pauleikhoff D; Pournaras CJ; Staurenghi G; Virgili G; Wolf S
Br J Ophthalmol; 2006 Sep; 90(9):1188-96. PubMed ID: 16929063
[TBL] [Abstract][Full Text] [Related]
5. [Comments on current therapeutic possibilities for neovascular age-related macula degeneration].
Klin Monbl Augenheilkd; 2006 Apr; 223(4):271-8. PubMed ID: 16639662
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
[No Abstract] [Full Text] [Related]
8. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Kaiser PK
Curr Med Res Opin; 2007 Mar; 23(3):477-87. PubMed ID: 17355729
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy in neovascular age-related macular degeneration.
Lin RC; Rosenfeld PJ
Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
[No Abstract] [Full Text] [Related]
11. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
[TBL] [Abstract][Full Text] [Related]
14. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
18. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
19. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.
Fung AE; Palanki R; Bakri SJ; Depperschmidt E; Gibson A
Ophthalmology; 2009 Feb; 116(2):286-96. PubMed ID: 19091408
[TBL] [Abstract][Full Text] [Related]
20. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
